Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
Healthcare
$4.55 +2.33%
+$0.11 today
- Market cap
- $463.38M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
52W Low $0.71High $8.33
Volume 1.39M
Average 0.69M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$39.88M
FY 2025 · Annual
Investing Cash Flow
-$7.89M
FY 2025 · Annual
Financing Cash Flow
$44.57M
FY 2025 · Annual
+5563.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Depreciation & Amortization | 1.38M | 3.07M | 4.04M | 3.83M | 3.69M |
| Deferred Income Tax | 3.04M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.47M | 6.46M | 6.94M | 9.55M | 7M |
| Change in Working Capital | (23.55M) | (4.46M) | (4.1M) | 3.02M | (785K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.87M | (2.84M) | (5.63M) | 832K | (318K) |
| Other Working Capital | (31.41M) | (1.62M) | 1.53M | 2.19M | (467K) |
| Other Non-Cash Items | 1.52M | 2.38M | (816K) | (1.5M) | (971K) |
| Operating Cash Flow | (57.12M) | (94.5M) | (81.23M) | (60.52M) | (39.88M) |
| Capital Expenditures | (7.93M) | (11.61M) | (407K) | (59K) | (71K) |
| Acquisitions (Net) | 2.52M | 104K | 0 | 0 | 0 |
| Purchases of Investments | (204.09M) | (132.38M) | (79.73M) | (93.55M) | (43.42M) |
| Sales of Investments | 201.58M | 193.33M | 191M | 85.1M | 35.6M |
| Other Investing Activities | (2.52M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (10.44M) | 49.44M | 110.86M | (8.51M) | (7.89M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.93M | 171K | 48.67M | (17K) | 44.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (53K) | 804K | (65K) |
| Financing Cash Flow | 1.93M | 171K | 48.62M | 787K | 44.57M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (65.63M) | (44.89M) | 78.25M | (68.24M) | (3.2M) |
| Free Cash Flow | (65.04M) | (106.11M) | (81.64M) | (60.57M) | (39.95M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$48.8M
+ D&A$3.7M
+ Stock-Based Comp$7.0M
+ Deferred Tax$0
- Working Capital-$785.0K
- Other Non-Cash-$971.0K
= Operating Cash Flow-$39.9M
- Capex-$71.0K
= Free Cash Flow-$40.0M
Analysis
FY2025 free cash flow is -$40.0M. FCF conversion is 81.9% of net income. Operating cash flow was -$39.9M, with capex of -$71.0K. The largest bridge item is Stock-Based Comp at $7.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| 10-Q | Quarterly report | Aug 11, 2026 |
Does STTK generate free cash flow?
Shattuck Labs, Inc. (STTK) generated -$39.95M of free cash flow in fiscal 2025.
How much operating cash flow does STTK produce?
Operating cash flow was -$39.88M, before capital expenditures of $71,000.00.
Continue the stock analysis
Jump to another research area for this company.